ReviewExpert opinion on biological therapy2014
Cardiovascular gene therapy for myocardial infarction.
Review in Expert opinion on biological therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 53 citations in OpenAlex.
- Plasmapheresis as a Potential Generalizable Therapy for Myocardial Infarction.Rejuvenation research · 2025Review
- KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome.European heart journal · 2024Article
- Current Landscape of Gene Therapy for the Treatment of Cardiovascular Disorders.Current gene therapy · 2024Review
- An Intrinsically Magnetic Epicardial Patch for Rapid Vascular Reconstruction and Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Cell-Based and Selected Cell-Free Therapies for Myocardial Infarction: How Do They Compare to the Current Treatment Options?International journal of molecular sciences · 2022Review
- Signaling pathways and targeted therapy for myocardial infarction.Signal transduction and targeted therapy · 2022Review
- Transthoracic ultrasound-guided percutaneous intramyocardial injection combined with ultrasound-targeted microbubble destruction-mediated angiogenin 1 gene therapy in canine myocardial infarction model.Cardiovascular diagnosis and therapy · 2021Article
- Elabela gene therapy promotes angiogenesis after myocardial infarction.Journal of cellular and molecular medicine · 2021Article
- Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine.Pharmaceutics · 2021Review
- Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy - current and future perspectives.Clinical science (London, England : 1979) · 2021Review
- A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene EditingNano letters · 2020Article
- Recent Development in Therapeutic Cardiac Patches.Frontiers in cardiovascular medicine · 2020Review
- p27kip1 haploinsufficiency preserves myocardial function in the early stages of myocardial infarction via Atg5‑mediated autophagy flux restoration.Molecular medicine reports · 2019Article
- Myocardial infarction stabilization by cell-based expression of controlled Vascular Endothelial Growth Factor levels.Journal of cellular and molecular medicine · 2018Article
- Expression of integrin-linked kinase improves cardiac function in a swine model of myocardial infarction.Experimental and therapeutic medicine · 2017Article
- Intramyocardial Injection of Recombinant Adeno-Associated Viral Vector Coexpressing PR39/Adrenomedullin Enhances Angiogenesis and Reduces Apoptosis in a Rat Myocardial Infarction Model.Oxidative medicine and cellular longevity · 2017Article
- Cardiac Regeneration using Growth Factors: Advances and Challenges.Arquivos brasileiros de cardiologia · 2016Review
- Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver.Biomaterials · 2016Review
- Gene therapy to restore electrophysiological function in heart failure.Expert opinion on biological therapy · 2015Review
- Stimulating endogenous cardiac repair.Frontiers in cell and developmental biology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionCardiovascular gene therapy is the third most popular application for gene therapy, representing 8.4% of all gene therapy trials as reported in 2012 estimates. Gene therapy in cardiovascular disease is aiming to treat heart failure from ischemic and non-ischemic causes, peripheral artery disease, venous ulcer, pulmonary hypertension, atherosclerosis and monogenic diseases, such as Fabry disease. AREAS COVERED: In this review, we will focus on elucidating current molecular targets for the treatment of ventricular dysfunction following myocardial infarction (MI). In particular, we will focus on the treatment of i) the clinical consequences of it, such as heart failure and residual myocardial ischemia and ii) etiological causes of MI (coronary vessels atherosclerosis, bypass venous graft disease, in-stent restenosis). EXPERT OPINION: We summarise the scheme of the review and the molecular targets either already at the gene therapy clinical trial phase or in the pipeline. These targets will be discussed below. Following this, we will focus on what we believe are the 4 prerequisites of success of any gene target therapy: safety, expression, specificity and efficacy (SESE).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.